ARGX

718.8

+0.96%↑

SHL.DE

34.96

-0.34%↓

PHIA

22.75

-0.91%↓

FRE

36.73

-0.97%↓

SRT3

239.6

+2.17%↑

ARGX

718.8

+0.96%↑

SHL.DE

34.96

-0.34%↓

PHIA

22.75

-0.91%↓

FRE

36.73

-0.97%↓

SRT3

239.6

+2.17%↑

ARGX

718.8

+0.96%↑

SHL.DE

34.96

-0.34%↓

PHIA

22.75

-0.91%↓

FRE

36.73

-0.97%↓

SRT3

239.6

+2.17%↑

ARGX

718.8

+0.96%↑

SHL.DE

34.96

-0.34%↓

PHIA

22.75

-0.91%↓

FRE

36.73

-0.97%↓

SRT3

239.6

+2.17%↑

ARGX

718.8

+0.96%↑

SHL.DE

34.96

-0.34%↓

PHIA

22.75

-0.91%↓

FRE

36.73

-0.97%↓

SRT3

239.6

+2.17%↑

Accueil・Liste d'Actions・Sanofi SA
Search

Sanofi SA

Fermé

SecteurSoins de santé

76.05 -1.64

Achat

Actualisation du prix 28 mai 2026, 15:29 UTC

AcheterVendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

75.57

Max

77.32

Chiffres clés

By Trading Economics

Revenu

-394M

1.6B

Ventes

-12B

11B

P/E

Moyenne du Secteur

19.273

50.102

BPA

1.34

Marge bénéficiaire

14.354

Employés

74,846

EBITDA

1.5B

2.7B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+24.76% upside

Dividendes

By Dow Jones

Prochains Résultats

30 juil. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-7.5B

91B

Ouverture précédente

77.69

Clôture précédente

76.05

Sentiment de l'Actualité

By Acuity

62%

38%

282 / 344 Classement par Healthcare

Sanofi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2026, 09:03 UTC

Résultats

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

DJ

Lire

29 avr. 2026, 05:27 UTC

Résultats

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

DJ

Lire

23 avr. 2026, 06:12 UTC

Résultats

Sanofi Posts Higher Sales Amid Leadership Transition

DJ

Lire

27 mai 2026, 20:34 UTC

Acquisitions, Fusions, Rachats

Webster Financial Stockholders Approve Sale to Banco Santander

DJ

Lire

7 mai 2026, 06:47 UTC

Market Talk
Acquisitions, Fusions, Rachats

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

DJ

Lire

1 mai 2026, 06:14 UTC

Acquisitions, Fusions, Rachats

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

DJ

Lire

1 mai 2026, 06:13 UTC

Acquisitions, Fusions, Rachats

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

DJ

Lire

1 mai 2026, 06:12 UTC

Acquisitions, Fusions, Rachats

Santander UK Financed Deal From Existing Cash Resources

DJ

Lire

1 mai 2026, 06:08 UTC

Acquisitions, Fusions, Rachats

Santander UK Announced Key Terms of Deal July 2025

DJ

Lire

1 mai 2026, 06:03 UTC

Acquisitions, Fusions, Rachats

Santander UK Buys TSB Banking for GBP2.65B

DJ

Lire

1 mai 2026, 06:02 UTC

Acquisitions, Fusions, Rachats

Santander UK Buys TSB Banking Group

DJ

Lire

29 avr. 2026, 12:01 UTC

Résultats

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

DJ

Lire

29 avr. 2026, 06:27 UTC

Market Talk
Résultats

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

DJ

Lire

29 avr. 2026, 04:55 UTC

Résultats

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

DJ

Lire

29 avr. 2026, 04:55 UTC

Résultats

Santander 1Q Loan Loss Provisions EUR3.225B

DJ

Lire

29 avr. 2026, 04:54 UTC

Résultats

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

DJ

Lire

29 avr. 2026, 04:54 UTC

Résultats

Santander 1Q Operating Expenses EUR6.48B

DJ

Lire

29 avr. 2026, 04:52 UTC

Résultats

Santander Backs 2028 View

DJ

Lire

29 avr. 2026, 04:52 UTC

Résultats

Santander Backs 2026 View

DJ

Lire

29 avr. 2026, 04:52 UTC

Résultats

Santander 1Q Underlying RoTE 15.2%

DJ

Lire

29 avr. 2026, 04:51 UTC

Résultats

Santander End-1Q CET1 Ratio 14.4%

DJ

Lire

29 avr. 2026, 04:51 UTC

Résultats

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

DJ

Lire

29 avr. 2026, 04:51 UTC

Résultats

Santander 1Q Net Interest Income EUR11.02B

DJ

Lire

29 avr. 2026, 04:50 UTC

Résultats

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

DJ

Lire

29 avr. 2026, 04:50 UTC

Résultats

Santander 1Q Underlying Pft EUR3.56B

DJ

Lire

29 avr. 2026, 04:49 UTC

Résultats

Santander 1Q Net Pft EUR5.455B

DJ

Lire

29 avr. 2026, 04:49 UTC

Résultats

Analysts Saw Santander 1Q Rev EUR15.00B

DJ

Lire

29 avr. 2026, 04:49 UTC

Résultats

Santander 1Q Rev EUR15.14B

DJ

Lire

27 avr. 2026, 09:32 UTC

Market Talk
Résultats

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

DJ

Lire

27 avr. 2026, 09:19 UTC

Market Talk

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

DJ

Lire

Comparaison

Variation de prix

Sanofi SA prévision

Objectif de Prix

By TipRanks

24.76% hausse

Prévisions sur 12 Mois

Moyen 95.22 EUR  24.76%

Haut 107 EUR

Bas 85 EUR

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

4

Achat

5

Maintien

0

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

282 / 344Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Autres valeurs du secteur

ARGX

Argenx SE

718.8

↑ +0.96%

SHL.DE

Siemens Healthineers AG

34.96

↓-0.34%

PHIA

Koninklijke Philips NV

22.75

↓-0.91%

FRE

Fresenius SE & Co KGaA

36.73

↓-0.97%

SRT3

Sartorius AG

239.6

↑ +2.17%
help-icon Live chat